These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Combined external beam radiotherapy and Pd-103 brachytherapy boost improves biochemical failure free survival in patients with clinically localized prostate cancer: results of a matched pair analysis. Singh AM; Gagnon G; Collins B; Niroomand-Rad A; McRae D; Zhang Y; Regan J; Lynch J; Dritschilo A Prostate; 2005 Jan; 62(1):54-60. PubMed ID: 15389809 [TBL] [Abstract][Full Text] [Related]
5. Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension. Dattoli M; Wallner K; True L; Cash J; Sorace R Urology; 2007 Feb; 69(2):334-7. PubMed ID: 17320673 [TBL] [Abstract][Full Text] [Related]
6. A permanent breast seed implant as partial-breast radiation therapy for early-stage patients: in regards to Keller et al. (Int J Radiat Oncol Biol Phys 2005;62:358-365). Godinez J; Gombos EC Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1611; author reply 1611. PubMed ID: 16580512 [No Abstract] [Full Text] [Related]
7. A permanent breast seed implant as partial breast radiation therapy for early-stage patients: a comparison of palladium-103 and iodine-125 isotopes based on radiation safety considerations. Keller B; Sankreacha R; Rakovitch E; O'brien P; Pignol JP Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):358-65. PubMed ID: 15890575 [TBL] [Abstract][Full Text] [Related]
9. In reply to Drs. Godinez and Gombos. Keller B Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1271. PubMed ID: 17145542 [No Abstract] [Full Text] [Related]
10. Dosimetric parameters as predictive factors for biochemical control in patients with higher risk prostate cancer treated with Pd-103 and supplemental beam radiation. Orio P; Wallner K; Merrick G; Herstein A; Mitsuyama P; Thornton K; Butler W; Sutlief S Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):342-6. PubMed ID: 17236959 [TBL] [Abstract][Full Text] [Related]
11. Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy. Corriveau J; Wallner K; Merrick G; True L; Cavanagh W; Sutlief S; Butler W Brachytherapy; 2003; 2(2):108-13. PubMed ID: 15062149 [TBL] [Abstract][Full Text] [Related]
12. High-dose-rate versus low-dose-rate monotherapy in the treatment of localized prostate cancer: The case for low-dose-rate monotherapy. Stock RG Brachytherapy; 2006; 5(1):5-6; discussion 8. PubMed ID: 16563989 [No Abstract] [Full Text] [Related]
13. [Will the postoperative sessions in the cobalt bomb become the past soon? Radiotherapy has changed]. MMW Fortschr Med; 2005 Mar; 147(10):10. PubMed ID: 15803776 [No Abstract] [Full Text] [Related]
14. High-dose-rate versus low-dose-rate monotherapy in the treatment of localized prostate cancer. The case for high-dose-rate monotherapy: An up and coming treatment option for low-risk prostate cancer. Sylvester JE Brachytherapy; 2006; 5(1):1-4; discussion 7. PubMed ID: 16563988 [No Abstract] [Full Text] [Related]
15. American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103. Rivard MJ; Butler WM; Devlin PM; Hayes JK; Hearn RA; Lief EP; Meigooni AS; Merrick GS; Williamson JF Brachytherapy; 2007; 6(1):34-7. PubMed ID: 17284383 [TBL] [Abstract][Full Text] [Related]
16. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy. Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266 [TBL] [Abstract][Full Text] [Related]
17. Calculated microdosimetric characteristics of 125I and 103Pd brachytherapy seeds at different depths in water. Wuu CS; Chen J Radiat Prot Dosimetry; 2006; 122(1-4):506-8. PubMed ID: 17189276 [TBL] [Abstract][Full Text] [Related]
18. Tolerance and acceptance results of a palladium-103 permanent breast seed implant Phase I/II study. Pignol JP; Rakovitch E; Keller BM; Sankreacha R; Chartier C Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1482-8. PubMed ID: 18930602 [TBL] [Abstract][Full Text] [Related]
19. A dosimetric analysis of unstranded seeds versus customized stranded seeds in transperineal interstitial permanent prostate seed brachytherapy. Heysek RV; Gwede CK; Torres-Roca J; Cantor A; Kelley S; Saini AS; Pow-Sang J Brachytherapy; 2006; 5(4):244-50. PubMed ID: 17118318 [TBL] [Abstract][Full Text] [Related]
20. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809. Hurwitz MD; Halabi S; Ou SS; McGinnis LS; Keuttel MR; Dibiase SJ; Small EJ Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):814-9. PubMed ID: 18407435 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]